ARTICLE | Finance

Seeking maturity

Why Taiwan Liposome is turning to NASDAQ for a dual listing

February 23, 2018 8:12 PM UTC

In need of funds to support a series of pivotal trials and finding the domestic market inhospitable to biotech, Taiwan Liposome Co. Ltd. (TPEx:4152) has chosen NASDAQ for a second listing.

On Feb. 16, the company proposed to raise up to $50 million through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw...

BCIQ Company Profiles

Taiwan Liposome Co. Ltd.